Dose: 15 to 60 g
Single Dose: 38 (37.5)
Frequency: As recommended.
Route: PO
Instructions: This is best provided by administering 15 g orally 1 to 4 times a day or 30 to 50 g rectally every 6 hours.

. It is of Synthetic origin. .

Sodium Polystyrene Sulphonate is contraindicated in conditions like Hypokalaemia,Hypersensitivity,Neonates,Bowel obstruction.

The severe or irreversible adverse effects of Sodium Polystyrene Sulphonate, which give rise to further complications include Cardiac arrhythmias, Hypokalemia, Potassium depletion, Irritability, Sodium retention.The signs and symptoms that are produced after the acute overdosage of Sodium Polystyrene Sulphonate include Fecal impaction, GI concretions.The symptomatic adverse reactions produced by Sodium Polystyrene Sulphonate are more or less tolerable and if they become severe, they can be treated symptomatically, these include Nausea, Vomiting, Anorexia, Diarrhea, Constipation, Confusion, ECG changes.

Sodium Polystyrene Sulphonate is primarily indicated in conditions like Hyperkalaemia, Oliguria.

Sodium Polystyrene Sulphonate is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAluminium Hydroxide and OxideCalcium CarbonateDigoxinDigoxinMagnesium Oxides and HydroxidesThyroxine (Na) These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Drug should not be given to patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Susp Store in a well closed container.

It should be used with caution in patients with renal failure and with conditions requiring a restricted sodium intake such as heart failure and severe hypertension. Patients receiving sodium polystyrene sulfonate should be monitored for electrolyte disturbances especially hypokalemia.